SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Templeton Mary B Esq (Last) (First) (Middle) 2600 KELLY RD (Street) WARRINGTON PA 18976 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/13/2011	3. Issuer Name and Ticker or Trading Symbol DISCOVERY LABORATORIES INC /DE/ [ DSCO ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Senior VP, General Counsel	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,000(1)	D
Common Stock	7,826(2)	I	By Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	03/27/2006	03/27/2016	Common Stock	3,333	115.5	D
Incentive Stock Option (right to buy)	05/17/2006	05/17/2016	Common Stock	444	33.75	D
Non-Qualified Stock Option (right to buy)	05/17/2006	05/17/2016	Common Stock	2,889	33.75	D
Non-Qualified Stock Option (right to buy)	12/15/2006	12/15/2016	Common Stock	4,667	36.9	D
Incentive Stock Option (right to buy)	06/21/2007	06/21/2017	Common Stock	1,000	49.05	D
Non-Qualified Stock Option (right to buy)	06/21/2007	06/21/2017	Common Stock	3,000	49.05	D
Incentive Stock Option (right to buy)	12/11/2007	12/11/2017	Common Stock	1,167	39.15	D
Non-Qualified Stock Option (right to buy)	12/11/2007	12/11/2017	Common Stock	3,500	39.15	D
Incentive Stock Option (right to buy)	12/12/2008	12/12/2018	Common Stock	741	18.15	D
Non-Qualified Stock Option (right to buy)	12/12/2008	12/12/2018	Common Stock	1,481	18.15	D
Incentive Stock Option (right to buy)	12/12/2008	12/12/2018	Common Stock	1,772	28.95	D
Non-Qualified Stock Option (right to buy)	12/12/2008	12/12/2018	Common Stock	2,672	28.95	D

Explanation of Responses:

1. Includes 6,667 Restricted Stock Awards, issued September 27,2010, that fully vest upon the earlier of (i) the second anniversary of the date of grant (ii) approval of Discovery Labs' New Drug Application for Surfaxin (R) for the prevention of RDS or (iii) the effective date of a strategic alliance, collaboration agreement or other similar arrangement between Discovery Labs and one of more third parties providing for the support for the development and/or commercialization of one or more of Discovery Lab's lead research and development programs - Surfaxin (R), Surfaxin LS (TM), and Aerosurf (R).

2. Shares reported represent issuer's matching stock contributions pursuant to its 401(k) program.

	Mary B> Templeton, Esq	09/22/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.